Leading Cogstate in our focus to optimize the measurement of cognition
Brad O’Connor has been Managing Director and Chief Executive Officer of Cogstate Limited since December 2005. He has responsibility for Cogstate’s overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business.
Darren Watson is Chief Financial Officer for Cogstate, responsible for the company’s financial strategy, driving business growth and ensuring proper governance and compliance. Mr. Watson leads all aspects of finance operations globally including corporate accounting, financial planning and analysis, internal audit, tax, insurance, and procurement.
Ben Bloomfield is the Chief Technology Officer at Cogstate. Leading a global technology team, Ben sets the strategic direction for the delivery of best in class technology solutions for our customers; in turn driving opportunities for revenue generation through technology enablement.
Tanya brings over 15 years’ experience in product development and operational management of clinical research to her role at Cogstate, specifically focussed on the measurement of cognition. She is skilled in new product and service implementation, leading and managing dynamic teams and process improvement initiatives.
Ken Billard is the Chief Commercial Officer for Cogstate, where he develops and executes strategies focused on expanding the adoption of Cogstate solutions to optimize the measurement of cognition and other clinical outcome assessments in pharmaceutical clinical trials.
Kate Jopling is Vice President of Operations for Clinical Trials at Cogstate. She has led the global Clinical Trials Operations division since 2014. In her role, Kate sets the strategic direction for delivery of products and services aimed at helping pharmaceutical clinical trials sponsors, CROs, and sites optimize the measurement of cognition with eClinical technologies and customized solutions.
Professor Paul Maruff is one of the founders of Cogstate. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioural and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods.
Dr. Edgar is an experienced leader in cognitive assessment and clinical endpoint strategy who provides expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through final analysis. Dr. Edgar is also a key advisor to Cogstate’s commercial and product teams for the development of new technologies.
Rachel brings more than 15 years of life science marketing strategy experience to her role at Cogstate, including marketing management roles at ICON plc (Nasdaq: ICLR), a global provider of outsourced development services to the biopharmaceutical industry.
Cogstate’s cognitive scientists and statisticians are experienced with all aspects of clinical conduct, from study design to cognitive data interpretation. Meet our team of accomplished neuropsychologists and clinicians.